Colorectal cancer is the third most common malignancy and the third-leading cause of cancer-related deaths worldwide. In the last several years, recombinant DNA technology has made cancer gene therapy feasible in the clinic. In our studies, we used both exogenous and endogenous canstatin, a type IV collagen genetically distinct product. We detected the effects of canstatin on colorectal cancer cells HCT-15 and HCT-116. DAPI staining, FCM and migration analyse were used to detect the apoptotic cells, cell cycle and mobility. As shown in the results, the apoptotic cell numbers (p<0.05) and G1 arrest cell numbers (p<0.05) were higher than in the non- treatment case. The mobility of the cells was also decreased obviously (p<0.05). Simultaneously, combination effects of exogenous and endogenous canstatin were identified.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
High prediagnostic dietary intake of vitamin B and vitamin B is associated with favorable prognosis of colorectal cancer among Chinese colorectal cancer patients.
Nutr Res
December 2024
Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China. Electronic address:
The potential impact of one-carbon metabolism (OCM)-related B vitamins (vitamin B, B, B, and folate) on colorectal cancer survival warrants investigation but research is sparse. This cohort study examined the association between the prediagnostic dietary intakes of OCM-related B vitamins and colorectal cancer survival. A total of 2799 colorectal cancer patients from the Guangdong Colorectal Cancer Cohort, enrolled at baseline in 2010, were followed for mortality outcomes through 2023.
View Article and Find Full Text PDFPatients With a Pathologic Near-Complete Response After Mandatory Total Mesorectal Excision Do Not Provide an Appropriate Control Group for Patients With Local Regrowth.
Dis Colon Rectum
February 2025
Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Biologic Therapy Is Associated With Improved Oncologic Outcomes in Crohn's Disease-Associated Colorectal Cancer.
Dis Colon Rectum
February 2025
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio.
Background: Patients with Crohn's disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer-related outcomes remains unclear.
Objective: To investigate the association between prior exposure to biologic treatment and colorectal cancer-related outcomes in patients with underlying Crohn's disease.
Leveraging Informative Phone Calls by Student Volunteers to Improve Colorectal Cancer Screening Compliance: A Case Study From the Veterans Health Administration.
Am J Med Qual
January 2025
Department of Hospital Medicine, VA Palo Alto Health Care System, Palo Alto, CA.
A novel microsatellite instability test of sebaceous tumours to facilitate low cost universal screening for Lynch syndrome.
Clin Exp Dermatol
January 2025
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Background: One in five sebaceous tumour (ST) patients may have Lynch syndrome (LS), a hereditary cancer predisposition. LS patients benefit from cancer surveillance and prevention programmes and immunotherapy. Whilst universal tumour mismatch repair (MMR) deficiency testing is recommended in colorectal and endometrial cancers to screen for LS, there is no consensus screening strategy for ST, leading to low testing rates and inequity of care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!